# Safety and Efficacy Study of BCD-066 Compared to Aranesp® for Anemia Treatment in Chronic Kidney Disease Patients

> **NCT02506868** · PHASE3 · COMPLETED · sponsor: **Biocad** · enrollment: 196 (actual)

## Conditions studied

- Chronic Kidney Disease
- End Stage Renal Failure on Dialysis
- Anemia

## Interventions

- **DRUG:** Darbepoetin alfa

## Key facts

- **NCT ID:** NCT02506868
- **Lead sponsor:** Biocad
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08-08
- **Primary completion:** 2017-01-08
- **Final completion:** 2017-12-21
- **Target enrollment:** 196 (ACTUAL)
- **Last updated:** 2020-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02506868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02506868, "Safety and Efficacy Study of BCD-066 Compared to Aranesp® for Anemia Treatment in Chronic Kidney Disease Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02506868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*